AML
News
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
Conference Coverage
Gilteritinib maintenance reduces relapse in MRD+ AML
Despite not meeting its primary endpoint, a trial in mutated acute myeloid leukemia showed the benefit of gilteritinib maintenance in certain...
Conference Coverage
CMML: GM-CSF inhibitor lenzilumab shows early promise
The PREACH-M trial has yielded encouraging preliminary results in treating CMML, a rare, “insidious” leukemia that can transform into AML.
Conference Coverage
‘Best’ for most APL patients: Chemo-free regimen
A chemo-free treatment regimen significantly improves survival over chemotherapy in patients with a rare, virulent leukemia, but those 50 and...
News
Widespread carboplatin, cisplatin shortages: NCCN survey
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.
Conference Coverage
ASCO honors Hagop Kantarjian, MD, for leukemia research
Noted Lebanese-American oncologist who leads the leukemia department at MD Anderson Cancer Center is to receive a top award at ASCO 2023.
News
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
News
AFib risk with cancer drugs underestimated
Many cancer therapies increase the risk of atrial fibrillation, but this is underreported in clinical trials.
News
Venetoclax shows promise for r/r hairy cell leukemia
Italian study suggests benefits of administering venetoclax for patients with r/r cases of hairy cell leukemia, a rare blood cancer,
News
Transplant vs. chemo: Similar AML survival rates
New study showed similar survival rates among AML patients treated solely with consolidation chemotherapy and those who received allogenic HCT.